eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
8/2002
vol. 6
 
Share:
Share:
abstract:

Fatal outcome of a hypersensitivity reaction to paclitaxel: a case report

Jan P. van Meerbeeck
,
Jeroen S. Kloover
,
Michael A. den Bakker

Współ Onkol (2002), vol. 6, 8, 486-489
Online publish date: 2003/04/11
View full text Get citation
 
Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this anti-tumor drug. Oral pre-medication with dexamethasone at a dose of 20 mg and given orally at 12 and 6 hours before infusion of paclitaxel have been shown to reduce the incidence of paclitaxel-induced HSRs significantly. However, due to logistic factors, short-course pre-medication with intravenously administered dexamethasone given 30 minutes prior to paclitaxel infusion became customary and retrospective analysis showed that this pre-medication schedule was as effective as the oral regimen. In this case report we describe the fatal outcome of a HSR in a patient receiving paclitaxel despite short-course pre-medication. The level of evidence supporting the short-course iv pre-medication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.
keywords:

hypersensitivity reaction, paclitaxel, anaphylaxis, dexamethasone, premedication, chemotherapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.